Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial

Edgard Diniba Dabira, Harouna M Soumare, Steven W Lindsay, Bakary Conteh, Fatima Ceesay, John Bradley, Christian Kositz, Henk Broekhuizen, Balla Kandeh, Alexandra E Fehr, Claudia Nieto-Sanchez, Joan Muela Ribera, Koen Peeters Grietens, Menno Roderick Smit, Chris Drakeley, Teun Bousema, Jane Achan, Umberto D'Alessandro, Edgard Diniba Dabira, Harouna M Soumare, Steven W Lindsay, Bakary Conteh, Fatima Ceesay, John Bradley, Christian Kositz, Henk Broekhuizen, Balla Kandeh, Alexandra E Fehr, Claudia Nieto-Sanchez, Joan Muela Ribera, Koen Peeters Grietens, Menno Roderick Smit, Chris Drakeley, Teun Bousema, Jane Achan, Umberto D'Alessandro

Abstract

Background: With a decline in malaria burden, innovative interventions and tools are required to reduce malaria transmission further. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) has been identified as a potential tool to further reduce malaria transmission, where coverage of vector control interventions is already high. However, the impact is limited in time. Combining an ACT with an endectocide treatment that is able to reduce vector survival, such as ivermectin (IVM), could increase the impact of MDA and offer a new tool to reduce malaria transmission.

Objective: The study objective is to evaluate the impact of MDA with IVM plus dihydroartemisinin-piperaquine (DP) on malaria transmission in an area with high coverage of malaria control interventions.

Methods: The study is a cluster randomized trial in the Upper River Region of The Gambia and included 32 villages (16 control and 16 intervention). A buffer zone of ~2 km was created around all intervention clusters. MDA with IVM plus DP was implemented in all intervention villages and the buffer zones; control villages received standard malaria interventions according to the Gambian National Malaria Control Program plans.

Results: The MDA campaigns were carried out from August to October 2018 for the first year and from July to September 2019 for the second year. Statistical analysis will commence once the database is completed, cleaned, and locked.

Conclusions: This is the first cluster randomized clinical trial of MDA with IVM plus DP. The results will provide evidence on the impact of MDA with IVM plus DP on malaria transmission.

Trial registration: ClinicalTrials.gov NCT03576313; https://ichgcp.net/clinical-trials-registry/NCT03576313.

International registered report identifier (irrid): DERR1-10.2196/20904.

Keywords: The Gambia; cluster randomized trial; dihydroartemisinin-piperaquine; ivermectin; malaria; mass drug administration.

Conflict of interest statement

Conflicts of Interest: None declared.

©Edgard Diniba Dabira, Harouna M Soumare, Steven W Lindsay, Bakary Conteh, Fatima Ceesay, John Bradley, Christian Kositz, Henk Broekhuizen, Balla Kandeh, Alexandra E Fehr, Claudia Nieto-Sanchez, Joan Muela Ribera, Koen Peeters Grietens, Menno Roderick Smit, Chris Drakeley, Teun Bousema, Jane Achan, Umberto D’Alessandro. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 19.11.2020.

References

    1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briët O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015 Oct 08;526(7572):207–211. doi: 10.1038/nature15535.
    1. World Malaria Report 2019. World Health Organization. [2020-05-31]. .
    1. Ceesay S, Casals-Pascual C, Erskine J, Anya S, Duah N, Fulford A, Sesay SS, Abubakar I, Dunyo S, Sey O, Palmer A, Fofana M, Corrah T, Bojang KA, Whittle HC, Greenwood BM, Conway DJ. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. The Lancet. 2008 Nov;372(9649):1545–1554. doi: 10.1016/s0140-6736(08)61654-2.
    1. Ceesay SJ, Casals-Pascual C, Nwakanma DC, Walther M, Gomez-Escobar N, Fulford AJC, Takem EN, Nogaro S, Bojang KA, Corrah T, Jaye MC, Taal MA, Sonko AAJ, Conway DJ. Continued decline of malaria in The Gambia with implications for elimination. PLoS One. 2010 Aug 18;5(8):e12242. doi: 10.1371/journal.pone.0012242.
    1. Mwesigwa J, Okebe J, Affara M, Di Tanna GL, Nwakanma D, Janha O, Opondo K, Grietens KP, Achan J, D'Alessandro U. On-going malaria transmission in The Gambia despite high coverage of control interventions: a nationwide cross-sectional survey. Malar J. 2015 Aug 14;14(1):314. doi: 10.1186/s12936-015-0829-6.
    1. Okebe J, Ribera JM, Balen J, Jaiteh F, Masunaga Y, Nwakanma D, Bradley J, Yeung S, Peeters Grietens K, D'Alessandro U. Reactive community-based self-administered treatment against residual malaria transmission: study protocol for a randomized controlled trial. Trials. 2018 Feb 20;19(1):126. doi: 10.1186/s13063-018-2506-x.
    1. Satoguina J, Walther B, Drakeley C, Nwakanma D, Oriero EC, Correa S, Corran P, Conway DJ, Walther M. Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau. Malar J. 2009 Dec 02;8(1):274. doi: 10.1186/1475-2875-8-274.
    1. The role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria. World Health Organization. [2020-05-31]. .
    1. Mass drug administration for falciparum malaria: a practical field manual. World Health Organization. [2020-05-31].
    1. Hung T, Davis T, Ilett K, Karunajeewa H, Hewitt S, Denis M, Lim C, Socheat D. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol. 2004 Mar;57(3):253–62. doi: 10.1046/j.1365-2125.2003.02004.x.
    1. Pryce J, Hine P. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2019 Jan 08;1:CD006404. doi: 10.1002/14651858.CD006404.pub3.
    1. Mwesigwa J, Achan J, Affara M, Wathuo M, Worwui A, Mohammed N, Kanuteh F, Prom A, Dierickx S, di Tanna GL, Nwakanma D, Bousema T, Drakeley C, Van Geertruyden JP, D'Alessandro U. Mass Drug Administration With Dihydroartemisinin-piperaquine and Malaria Transmission Dynamics in The Gambia: A Prospective Cohort Study. Clin Infect Dis. 2019 Jul 02;69(2):278–286. doi: 10.1093/cid/ciy870.
    1. Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, Shanks GD, Slutsker L, Kachur SP, Wegbreit J, Ippolito MM, Poirot E, Gosling R. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg. 2015 Jul;93(1):125–134. doi: 10.4269/ajtmh.14-0254.
    1. Eisele T, Bennett A, Silumbe K, Finn T, Chalwe V, Kamuliwo M, Hamainza B, Moonga H, Kooma E, Chizema Kawesha E, Yukich J, Keating J, Porter T, Conner RO, Earle D, Steketee RW, Miller JM. Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial. J Infect Dis. 2016 Dec 15;214(12):1831–1839. doi: 10.1093/infdis/jiw416.
    1. Slater HC, Foy BD, Kobylinski K, Chaccour C, Watson OJ, Hellewell J, Aljayyoussi G, Bousema T, Burrows J, D'Alessandro U, Alout H, Ter Kuile FO, Walker PGT, Ghani AC, Smit MR. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Lancet Infect Dis. 2020 Apr;20(4):498–508. doi: 10.1016/S1473-3099(19)30633-4.
    1. Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Chen T, Bousema T, Slater HC, Waterhouse D, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ward SA, ter Kuile Fo. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases. 2018 Jun;18(6):615–626. doi: 10.1016/S1473-3099(18)30163-4.
    1. Ivermectin for malaria transmission control. World Health Organization. [2020-05-31]. .
    1. Chaccour CJ, Rabinovich NR, Slater H, Canavati SE, Bousema T, Lacerda M, Ter Kuile F, Drakeley C, Bassat Q, Foy BD, Kobylinski K. Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda. Malar J. 2015 Jun 11;14:243. doi: 10.1186/s12936-015-0691-6.
    1. Alout H, Krajacich BJ, Meyers JI, Grubaugh ND, Brackney DE, Kobylinski KC, Diclaro JW, Bolay FK, Fakoli LS, Diabaté A, Dabiré RK, Bougma RW, Foy BD. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malar J. 2014 Nov 03;13:417. doi: 10.1186/1475-2875-13-417.
    1. Ouédraogo AL, Bastiaens GJH, Tiono AB, Guelbéogo WM, Kobylinski KC, Ouédraogo A, Barry A, Bougouma EC, Nebie I, Ouattara MS, Lanke KHW, Fleckenstein L, Sauerwein RW, Slater HC, Churcher TS, Sirima SB, Drakeley C, Bousema T. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis. 2015 Feb 01;60(3):357–65. doi: 10.1093/cid/ciu797.
    1. Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. The Lancet. 2019 Apr;393(10180):1517–1526. doi: 10.1016/s0140-6736(18)32321-3.
    1. Hayes RJ, Moulton LH. Chapman and Hall/CRC. Florida, USA: Chapman and Hall/CRC; 2017. Cluster Randomised Trials, Second Edition.
    1. Pinder M, Conteh L, Jeffries D, Jones C, Knudsen J, Kandeh B, Jawara M, Sicuri E, D'Alessandro U, Lindsay SW. The RooPfs study to assess whether improved housing provides additional protection against clinical malaria over current best practice in The Gambia: study protocol for a randomized controlled study and ancillary studies. Trials. 2016 Jun 03;17(1):275. doi: 10.1186/s13063-016-1400-7.
    1. Mwesigwa J, Achan J, Di Tanna GL, Affara M, Jawara M, Worwui A, Hamid-Adiamoh M, Kanuteh F, Ceesay S, Bousema T, Drakeley C, Grietens KP, Lindsay SW, Van Geertruyden JP, D'Alessandro U. Residual malaria transmission dynamics varies across The Gambia despite high coverage of control interventions. PLoS One. 2017 Nov 2;12(11):e0187059. doi: 10.1371/journal.pone.0187059.
    1. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS Med. 2015 Mar 3;12(3):e1001788. doi: 10.1371/journal.pmed.1001788.
    1. Daniels R, Ndiaye D, Wall M, McKinney J, Séne PD, Sabeti PC, Volkman SK, Mboup S, Wirth DF. Rapid, Field-Deployable Method for Genotyping and Discovery of Single-Nucleotide Polymorphisms Associated with Drug Resistance in Plasmodium falciparum. Antimicrob. Agents Chemother. 2012 Mar 19;56(6):2976–2986. doi: 10.1128/aac.05737-11.
    1. Detinova TS. Age-grouping methods in Diptera of medical importance with special reference to some vectors of malaria. Monogr Ser World Health Organ. 1962;47:13–191.
    1. Mboera LE, Kihonda J, Braks MA, Knols BG. Short report: Influence of centers for disease control light trap position, relative to a human-baited bed net, on catches of Anopheles gambiae and Culex quinquefasciatus in Tanzania. Am J Trop Med Hyg. 1998 Oct;59(4):595–6. doi: 10.4269/ajtmh.1998.59.595.
    1. Schulz J, Coulibaly J, Schindler C, Wimmersberger D, Keiser J. Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. J Antimicrob Chemother. 2019 Jun 01;74(6):1642–1647. doi: 10.1093/jac/dkz083.
    1. Tetelbaum M, Finkelstein Y, Nava-Ocampo AA, Koren G. Back to basics: understanding drugs in children: pharmacokinetic maturation. Pediatr Rev. 2005 Sep 01;26(9):321–8. doi: 10.1542/pir.26-9-321.
    1. Smit MR, Ochomo E, Aljayyoussi G, Kwambai T, Abong'o B, Bayoh N, Gimnig J, Samuels A, Desai M, Phillips-Howard PA, Kariuki S, Wang D, Ward S, Ter Kuile FO. Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. JMIR Res Protoc. 2016 Nov 17;5(4):e213. doi: 10.2196/resprot.6617.
    1. Wu L, Hall T, Ssewanyana I, Oulton T, Patterson C, Vasileva H, Singh S, Affara M, Mwesigwa J, Correa S, Bah M, D'Alessandro U, Sepúlveda N, Drakeley C, Tetteh KKA. Optimisation and standardisation of a multiplex immunoassay of diverse Plasmodium falciparum antigens to assess changes in malaria transmission using sero-epidemiology. Wellcome Open Res. 2019 Feb 8;4:26. doi: 10.12688/wellcomeopenres.14950.1.
    1. Kobylinski KC, Jittamala P, Hanboonkunupakarn B, Pukrittayakamee S, Pantuwatana K, Phasomkusolsil S, Davidson SA, Winterberg M, Hoglund RM, Mukaka M, van der Pluijm RW, Dondorp A, Day NP, White NJ, Tarning J. Safety, Pharmacokinetics, and Mosquito-Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects. Clin Pharmacol Ther. 2020 May 27;107(5):1221–1230. doi: 10.1002/cpt.1716.
    1. The Ivermectin Roadmappers A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool. Am J Trop Med Hyg. 2020 Feb;102(2s):3–24. doi: 10.4269/ajtmh.19-0620.
    1. How to Design Vector Control Efficacy Trials. World Health Organization. [2020-05-31]. .
    1. Wolbers M, Kleinschmidt I, Simmons CP, Donnelly CA. Considerations in the design of clinical trials to test novel entomological approaches to dengue control. PLoS Negl Trop Dis. 2012 Nov 29;6(11):e1937. doi: 10.1371/journal.pntd.0001937.
    1. Stevenson JC, Stresman GH, Baidjoe A, Okoth A, Oriango R, Owaga C, Marube E, Bousema T, Cox J, Drakeley C. Use of different transmission metrics to describe malaria epidemiology in the highlands of western Kenya. Malar J. 2015 Oct 26;14(1):418. doi: 10.1186/s12936-015-0944-4.
    1. Tusting L, Bousema T, Smith D, Drakeley C. Measuring changes in Plasmodium falciparum transmission: precision, accuracy and costs of metrics. Adv Parasitol. 2014;84:151–208. doi: 10.1016/B978-0-12-800099-1.00003-X.
    1. Perraut R, Varela M, Loucoubar C, Niass O, Sidibé A, Tall A, Trape J, Wotodjo AN, Mbengue B, Sokhna C, Vigan-Womas I, Touré A, Richard V, Mercereau-Puijalon O. Serological signatures of declining exposure following intensification of integrated malaria control in two rural Senegalese communities. PLoS One. 2017 Jun 13;12(6):e0179146. doi: 10.1371/journal.pone.0179146.
    1. Tshefu A, Gaye O, Kayentao K, Thompson R, Bhatt K, Sesay S, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. The Lancet. 2010 Apr;375(9724):1457–1467. doi: 10.1016/s0140-6736(10)60322-4.
    1. Khagayi S, Desai M, Amek N, Were V, Onyango E, Odero C, Otieno K, Bigogo G, Munga S, Odhiambo F, Hamel MJ, Kariuki S, Samuels AM, Slutsker L, Gimnig J, Vounatsou P. Modelling the relationship between malaria prevalence as a measure of transmission and mortality across age groups. Malar J. 2019 Jul 23;18(1):247. doi: 10.1186/s12936-019-2869-9.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe